Trials & Filings
Related Searches:
Filter by:
241 - 255 of 604 results
May 20, 2009
Two studies provide data for Rituxan's benefits in Progression Free Survival in chronic lymphocytic leukemia.
Read More »
May 15, 2009
Enzon Pharmaceuticals, Inc. received approval from the FDA for Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Read More »
May 11, 2009
Eurand received approval from the FDA for EUR-1048, to be marketed as GlaxoSmithKline's Lamictal ODT (lamotrigine) Orally Disintegrating Tablets.
Read More »
May 8, 2009
Gilead's DAR-311 (DORADO) Phase III trial evaluating its once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, achieved positive results.
Read More »
May 7, 2009
Merck Serono and partner Newron Pharmaceuticals SpA have initiated the SETTLE study to evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as an add-on therapy to levodopa, in mid- to late-stage Parkinson's disease patien
Read More »
May 5, 2009
Merck Serono, a division of Merck KGaA, has launched Glucophage Powder for Oral Solution in Sachets, indicated for the first-line treatment of type 2 diabetes mellitus, in France and the UK.
Read More »
May 4, 2009
AstraZeneca submitted an NDA to the FDA seeking approval for low-dose aspirin combined with esomeprazole magnesium (Nexium) to reduce the risk of low-dose aspirin-associated side effects, such as gastric and/or duodenal ulcers.
Read More »
April 27, 2009
Wyeth received marketing authorization from the European Commission for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.
Read More »
April 23, 2009
Sandoz Canada received market authorization for Omnitrope in Canada. Omnitrope is the first biosimilar of a previously approved recombinant drug to be approved by Health Canada under Subsequent Entry Biologic (SEB).
Read More »
April 22, 2009
Genentech's Phase III study of Avastin (bevacizumab) plus chemotherapy in patients with early-stage colon cancer (NSABP C-08) did not meet its primary endpoint of reducing the risk of cancer returning.
Read More »
April 17, 2009
Gilead Sciences has begun enrollment in a Phase II trial of its investigational integrase-based, single-tablet, once-daily regimen of elvitegravir, GS 9350 and Truvada for the treatment of HIV-1 infection.
Read More »
April 3, 2009
Gilead Sciences' Phase III DAR-311 (DORADO) study evaluating its endothelin receptor antagonist (ERA) darusentan for the treatment of resistant hypertension, met its co-primary efficacy endpoints.
Read More »
April 1, 2009
Wyeth submitted a BLA to the FDA for Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein).
Read More »
March 25, 2009
Wyeth Pharmaceuticals received approval from the FDA for Tygacil (tigecycline) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.
Read More »
March 23, 2009
Forest Laboratories received approval from the FDA for its sNDA for Lexapro for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, ages 12 to 17.
Read More »
241 - 255 of 604 results
